Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice-Reference-Cited by-同舟云学术

Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice

Published:2023-10-26 Issue:1 Volume:41 Page:198-214
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Semler Oliver^ORCID,Cormier-Daire Valérie,Lausch Ekkehart,Bober Michael B.^ORCID,Carroll Ricki^ORCID,Sousa Sérgio B.^ORCID,Deyle David,Faden Maha,Hartmann Gabriele,Huser Aaron J.,Legare Janet M.^ORCID,Mohnike Klaus,Rohrer Tilman R.^ORCID,Rutsch Frank,Smith Pamela^ORCID,Travessa Andre M.^ORCID,Verardo Angela,White Klane K.,Wilcox William R.,Hoover-Fong Julie^ORCID

Funder

BioMarin Pharmaceutical

Universitätsklinikum Köln

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02705-9.pdf

Reference41 articles.

1. Coi A, Santoro M, Garne E, et al. Epidemiology of achondroplasia: a population-based study in Europe. Am J Med Genet A. 2019;179:1791–8.

2. Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182A:2297–316.